Calliditas Therapeutics AB
STO:CALTX

Watchlist Manager
Calliditas Therapeutics AB Logo
Calliditas Therapeutics AB
STO:CALTX
Watchlist
Price: 208 SEK 0.87%
Market Cap: 12.5B SEK

EV/EBIT
Enterprise Value to EBIT

-35.9
Current
-19.5
Median
16.7
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-35.9
=
Enterprise Value
12.7B SEK
/
EBIT
-353.1m SEK
EBIT Growth EV/EBIT to Growth
SE
Calliditas Therapeutics AB
STO:CALTX
Average EV/EBIT: 1 870.6
Negative Multiple: -35.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
29.2
33%
0.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
18.5
14%
1.3
CH
Roche Holding AG
SIX:ROG
10.6
6%
1.8
UK
AstraZeneca PLC
LSE:AZN
169.3
23%
7.4
CH
Novartis AG
SIX:NOVN
13.8
10%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
10.6
14%
0.8
US
Merck & Co Inc
NYSE:MRK
9.7
9%
1.1
IE
E
Endo International PLC
LSE:0Y5F
731.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
9%
1.1

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
70.6
2-Years Forward
EV/EBIT
10.1
3-Years Forward
EV/EBIT
5.1